二甲双胍对早期糖尿病肾病的治疗作用

目的:观察二甲双胍对早期糖尿病肾病的治疗作用并初探其机理。方法:32例早期糖尿病肾病患者经过2周的导入期后进入观察期,随机分为α-糖苷酶抑制剂组(α-Gls组)和二甲双胍组(Met组)。观察两组患者治疗前后体重指数(BMI)、空腹血糖(FPG)、糖化血红蛋白(HbA1C)、血清C反应蛋白(CRP)、纤维蛋白原(Fg)、尿微量白蛋白(mAlb)变化。结果:Met组治疗前后BMI、FPG、HbA1C变化明显:血CRP分别是(3.57±0.45)mg/L和(1.79±0.34)mg/L(P<0.05),血Fg分别是(4.79±0.57)g/L和(3.05±0.35)g/L(P<0.05),尿mAlb分别是(273±46.24)mg/24h和(104±35.11)mg/24h(P<0.05);α-Gls组治疗前后CRP、Fg、mAlb无明显变化。结论:二甲双胍可通过改善高凝状态、抗炎来治疗早期糖尿病肾病。

Metformin treatment of early diabetic nephrophathy

Objective To evaluate Metformin treatment of early diabetic nephrophathy and its mechanism.Method After induction period of two weeks,32 patients with early diabetic nephrophathy were divided into α-glycosidase inhibitor group(α-Gls group)and Metformin group(Met group).The biochemical parameters including fasting plasma glucose(FPG),glycosylated hemoglobin C(HbA1C),C-reactive protein(CRP),fibrinogen(Fg),urine albumin(mAlb) and body mass index(BMI) were examined before and after therapy.Results CRP,Fg and mAlb in Met group before and after treatment showed significant difference(P<0.05).CRP was(3.57±0.45)mg/L vs(1.79±0.34)mg/L;Fg was(4.79±0.57)g/L vs(3.05±0.35)g/L;mAlb was(273±46.24)mg/24h vs(104±35.11)mg/24h.There were no significant changes in CRP,Fg and mAlb in α-Gls group.Conclusion Metformin can treat early diabetic nephrophathy through lowing Fg and anti-inflammation.